drugset / Trial / NCT04723602

Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults

NCT04723602 ↗

Non-randomizedParallel-groupOpen-labelPrevention

Summary

Primary Objective: • To evaluate the safety and tolerability of cAd3-EBO-S and cAd3 Marburg vaccines when administered Intramuscular (IM) at a dose of 1 x 10\^11 particle units (PU) to healthy adults. Secondary Objectives: * To evaluate the antibody response to Monovalent Chimpanzee Adenoviral Vectored Filovirus Ebola-S (cAd3-EBO-S) and Monovalent Chimpanzee Adenoviral Vectored Filovirus (Marburg) (cAd3 Marburg) vaccines as assessed by antigen glycoprotein (GP) specific (enzyme-linked immunosorbent assay) ELISA * To collect sufficient post-vaccination plasma to support further development of filovirus assays

Timeline

Start
2021-01-06
Primary completion
2021-12-14
Completion
2021-12-14

Drugs

EvaluationDrugModalityDoseRoute
Comparator cAd3-EBO S Vaccine 1e+11 unknown Intramuscular
Comparator cAd3-Marburg Vaccine 1e+11 unknown Intramuscular